Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Products under Development by Stage of Development | 7 | 1 |
| N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Products under Development by Therapy Area | 8 | 1 |
| N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Products under Development by Indication | 9 | 1 |
| N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Products under Development by Companies | 12 | 2 |
| N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Therapeutics Assessment | 14 | 7 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 2 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Companies Involved in Therapeutics Development | 21 | 5 |
| Abeona Therapeutics, Inc. | 21 | 1 |
| ArmaGen Inc. | 22 | 1 |
| Laboratorios Del Dr. Esteve S.A. | 23 | 1 |
| Lysogene | 24 | 1 |
| Shire Plc | 25 | 1 |
| N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Drug Profiles | 26 | 7 |
| ABO-102 Drug Profile | 26 | 2 |
| AGT-184 Drug Profile | 28 | 1 |
| EGT-101 Drug Profile | 29 | 1 |
| LYSSAF-301 Drug Profile | 30 | 1 |
| LYSSAF-302 Drug Profile | 31 | 1 |
| SHP-610 Drug Profile | 32 | 1 |
| N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Featured News &Press Releases | 33 | 11 |
| Aug 04, 2016: Abeona Therapeutics Announces European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome Type A (MPS IIIA) | 33 | 1 |
| Aug 02, 2016: Abeona Therapeutics Provides Update on Initial Subjects in Sanfilippo Type A Gene Therapy Trial, Demonstrating Encouraging Early Biopotency Signals | 33 | 1 |
| Jul 06, 2016: Lysogene Begins Multi-National Observational Study as it Prepares to Initiate Pivotal Clinical Trial for the Treatment of Sanfilippo Type A | 34 | 1 |
| May 23, 2016: Abeona Therapeutics to Present at UBS 2016 Global Healthcare Conference | 35 | 1 |
| May 17, 2016: Abeona Therapeutics Doses First Patient in Phase 1/2 Trial With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA) | 35 | 1 |
| Apr 15, 2016: Abeona Therapeutics to Present at Gene, Cell and Molecular Therapies for Inherited Metabolic Diseases Meeting | 36 | 1 |
| Feb 29, 2016: Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Systemic AAV Phase I/II Clinical Study With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA) | 37 | 1 |
| Feb 25, 2016: ESTEVE Provides Update On EGT-101 For Sanfilippo A Syndrome | 38 | 1 |
| Jan 11, 2016: Abeona Therapeutics Announces European Regulatory Approval for ABO-102 for patients with Sanfilippo syndrome | 39 | 1 |
| Nov 24, 2015: Lysogene Receives Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA | 40 | 1 |
| Jul 21, 2015: Lysogene and Alcyone Lifesciences Enter into a Collaboration for Mucopolysaccharidosis Type IIIA (MPS IIIA) | 40 | 1 |
| May 20, 2015: PlasmaTech Biopharmaceuticals Announces Orphan Drug and Rare Pediatric Disease Designations For ABX-102 From FDA | 41 | 1 |
| Oct 09, 2013: Abeona Therapeutics and Nationwide Childrens Hospital receive prestigious Global Genes Champions of Hope award for Patient Advocacy | 41 | 1 |
| Jun 18, 2012: Lysogene Completes Enrollment In Phase I/II Clinical Trial Of SAF-301 In Sanfilippo Type A Syndrome | 42 | 1 |
| Apr 16, 2011: Lysogene Launches First Gene Therapy Clinical Trial Of SAF-301 To Treat Sanfilippo Disease | 42 | 2 |
| Appendix | 44 | 2 |
| Methodology | 44 | 1 |
| Coverage | 44 | 1 |
| Secondary Research | 44 | 1 |
| Primary Research | 44 | 1 |
| Expert Panel Validation | 44 | 1 |
| Contact Us | 44 | 1 |
| Disclaimer | 45 | 1 |
